$0.61
8.29% today
Nasdaq, Apr 04, 08:49 pm CET
ISIN
US92731L1061
Symbol
VINC
Sector
Industry

Vincerx Pharma Inc Stock price

$0.66
-0.10 13.20% 1M
-13.65 95.39% 6M
-4.60 87.45% YTD
-131.34 99.50% 1Y
-77.54 99.16% 3Y
-186.34 99.65% 5Y
-186.34 99.65% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
+0.03 4.73%
ISIN
US92731L1061
Symbol
VINC
Sector
Industry

Key metrics

Market capitalization $3.45m
Enterprise Value $-1.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.06
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-31.46m
Free Cash Flow (TTM) Free Cash Flow $-26.13m
Cash position $5.07m
EPS (TTM) EPS $-19.56
Short interest 3.00%
Show more

Is Vincerx Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Vincerx Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Vincerx Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Vincerx Pharma Inc:

Buy
100%

Financial data from Vincerx Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.09 1.09
18% 18%
-
-1.09 -1.09
18% 18%
-
- Selling and Administrative Expenses 15 15
17% 17%
-
- Research and Development Expense 14 14
49% 49%
-
-30 -30
27% 27%
-
- Depreciation and Amortization 1.09 1.09
18% 18%
-
EBIT (Operating Income) EBIT -31 -31
26% 26%
-
Net Profit -30 -30
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vincerx Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vincerx Pharma Inc Stock News

Neutral
GlobeNewsWire
17 days ago
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and Q...
Neutral
GlobeNewsWire
about one month ago
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated.
Neutral
GlobeNewsWire
2 months ago
Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025
More Vincerx Pharma Inc News

Company Profile

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed Hamdy, Raquel Izumi, Tom Thomas, Stuart Hwang, and John Byrd in 2018 and is headquartered in Palo Alto, CA.

Head office United States
CEO Raquel Izumi
Employees 13
Founded 2018
Website vincerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today